SILO stock forecast, quote, news & analysis
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases... Show more
Why Silo Pharma (SILO) Stock Is Up +11% in the Last 30 Days
Key Takeaways
- Silo Pharma (SILO) shares have risen roughly 11% over the past 30 days, rebounding from a 52-week low near $1.10 reached in mid-October.
- The advance followed new U.S. and Canadian patent allowances for its lead PTSD candidate, SPC-15, plus progress on its QwikAgents AI platform.
- A recently completed $815,000 private placement strengthened working capital but also introduced incremental share dilution.
- The 30-day gain stands in contrast to a longer multi-month downtrend, with shares still sharply lower over the trailing quarter and year.
- Investors are watching the company's upcoming quarterly report and further pipeline, financing, and listing-compliance updates.
- Get additional details on Price Targets, Earnings, and Forecast for SILO.
- Explore Trending AI Robots to see automated strategies currently trading this and other tickers.
Silo Pharma (SILO) Company Overview and Market Position
Silo Pharma, Inc. is a developmental-stage biopharmaceutical company headquartered in Sarasota, Florida, that also maintains a cryptocurrency treasury strategy. Its therapeutic pipeline targets underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety, fibromyalgia, and central nervous system diseases. The lead program, SPC-15, is an intranasal serotonin 4 (5-HT4) receptor agonist being developed for PTSD and stress-induced anxiety, while SP-26 is a time-release ketamine-based implant for fibromyalgia and chronic pain. Preclinical assets include SPC-14 for Alzheimer's disease and SPU-16 for multiple sclerosis, with research conducted through collaborations including Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore.
Investors follow SILO primarily for the optionality of its early-stage clinical and intellectual-property milestones rather than current revenue, which remains minimal. The company is a micro-cap with a small share count, and its shares trade on the Nasdaq Capital Market, where they have experienced substantial volatility and a wide 52-week range of roughly $1.10 to $10.43.
Silo Pharma (SILO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, SILO has gained approximately 11%, climbing from about $1.47 to $1.63 on a closing basis. The move has not been linear: the stock touched a 52-week low of $1.10 in mid-October before stabilizing, and it later rallied more than 20% in a single session on elevated volume.
The short-term rebound contrasts with the stock's longer trend. Over the trailing quarter, shares have fallen roughly 57%, extending a broader decline that has left SILO sharply lower on a year-to-date basis. The recent 30-day recovery therefore represents a bounce from depressed levels rather than a reversal of the multi-month downtrend.
What Drove SILO Stock Price in the Last 30 Days
Several verified developments supported the recent move. In September, the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering SPC-15, its lead PTSD asset, and the Canadian Intellectual Property Office issued a separate notice of allowance for the same program. These steps strengthen the company's intellectual-property position around its most advanced candidate.
Separately, the company announced that its QwikAgents platform expanded its AI-agent offering to include support for NVDA (NVIDIA) models, connecting the stock to investor enthusiasm around artificial intelligence. In early November, Silo completed a private placement that raised approximately $815,000 in net proceeds through shares and pre-funded warrants, reinforcing its working capital even as it introduced incremental dilution. The combination of patent news, AI-related momentum, a fresh capital injection, and a recovery from deeply oversold levels contributed to the stock's 30-day advance.
What Drove SILO Stock Performance Over the Last Quarter
The broader quarterly picture is dominated by a steep decline. After spiking toward the upper single digits in July, shares unwound rapidly through August, September, and October as momentum faded and selling pressure mounted in the micro-cap name. Financing overhang, concerns about Nasdaq listing compliance, limited revenue, ongoing net losses, and volatility in the company's cryptocurrency holdings all weighed on sentiment. The company has since indicated it regained Nasdaq minimum bid-price compliance and completed a capital raise, but the multi-month trajectory remains sharply negative even after the recent bounce.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's AI-driven trading bots. Tickeron offers hundreds of automated bots that trade thousands of tickers, yet only the top-performing and most relevant strategies appear in this section. The bots differ by strategy, timeframe, and performance metrics, giving traders a way to compare automated approaches across markets. For investors monitoring volatile micro-cap and biotech names, the page offers a view of how algorithmic strategies are positioning. Explore the section to see the AI robots currently drawing attention.
SILO Stock Forecast Drivers: What Investors Should Watch Next
Going forward, investors are likely to monitor the company's upcoming quarterly results and any updates on SPC-15 clinical progress and additional patent activity. The commercialization path for the QwikAgents AI platform, future financing needs and cash runway, and the execution of the authorized share repurchase program are also key factors. Because the company holds digital assets, price moves in major cryptocurrencies can affect reported results, while its micro-cap share structure can amplify volatility. Maintaining Nasdaq listing compliance and managing dilution from outstanding warrants remain important considerations. These are factors to watch, not a forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for SILO turns positive, indicating new upward trend
SILO saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned positive. In 89 of the 102 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
SILO moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +37.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where SILO advanced for three days, in 213 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SILO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SILO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SILO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. SILO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.466) is normal, around the industry mean (3.498). P/E Ratio (-0.348) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (3.910) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (28.736) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SILO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology